

Bioengineered Protein Drugs-China Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/B7A2AC2AC33EN.html>

Date: February 2018

Pages: 154

Price: US\$ 2,980.00 (Single User License)

ID: B7A2AC2AC33EN

Abstracts

Report Summary

Bioengineered Protein Drugs-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bioengineered Protein Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Bioengineered Protein Drugs 2013-2017, and development forecast 2018-2023

Main market players of Bioengineered Protein Drugs in China, with company and product introduction, position in the Bioengineered Protein Drugs market

Market status and development trend of Bioengineered Protein Drugs by types and applications

Cost and profit status of Bioengineered Protein Drugs, and marketing status

Market growth drivers and challenges

The report segments the China Bioengineered Protein Drugs market as:

China Bioengineered Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North China

Northeast China

East China

Central & South China

Southwest China
Northwest China

China Bioengineered Protein Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Therapeutic Proteins
Monoclonal Antibodies
Vaccines

China Bioengineered Protein Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Diabetes and Hormonal Disorders
Genetic and Fertility Disorders
Cancers
Organ Transplants
Others

China Bioengineered Protein Drugs Market: Players Segment Analysis (Company and Product introduction, Bioengineered Protein Drugs Sales Volume, Revenue, Price and Gross Margin):

Abbott Laboratories
F. Hoffmann-La Roche Ltd
Amgen, Inc.
Bayer AG
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
Biocon Ltd.
Eli Lilly and Company
Sanofi
GlaxoSmithKline plc
Johnson & Johnson
JanssenNovartis AG
Panacea Biotec
ProBioGen AG

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BIOENGINEERED PROTEIN DRUGS

- 1.1 Definition of Bioengineered Protein Drugs in This Report
- 1.2 Commercial Types of Bioengineered Protein Drugs
 - 1.2.1 Therapeutic Proteins
 - 1.2.2 Monoclonal Antibodies
 - 1.2.3 Vaccines
- 1.3 Downstream Application of Bioengineered Protein Drugs
 - 1.3.1 Diabetes and Hormonal Disorders
 - 1.3.2 Genetic and Fertility Disorders
 - 1.3.3 Cancers
 - 1.3.4 Organ Transplants
 - 1.3.5 Others
- 1.4 Development History of Bioengineered Protein Drugs
- 1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023
 - 1.5.1 China Bioengineered Protein Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023

CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Bioengineered Protein Drugs in China 2013-2017
- 2.2 Consumption Market of Bioengineered Protein Drugs in China by Regions
 - 2.2.1 Consumption Volume of Bioengineered Protein Drugs in China by Regions
 - 2.2.2 Revenue of Bioengineered Protein Drugs in China by Regions
- 2.3 Market Analysis of Bioengineered Protein Drugs in China by Regions
 - 2.3.1 Market Analysis of Bioengineered Protein Drugs in North China 2013-2017
 - 2.3.2 Market Analysis of Bioengineered Protein Drugs in Northeast China 2013-2017
 - 2.3.3 Market Analysis of Bioengineered Protein Drugs in East China 2013-2017
 - 2.3.4 Market Analysis of Bioengineered Protein Drugs in Central & South China 2013-2017
 - 2.3.5 Market Analysis of Bioengineered Protein Drugs in Southwest China 2013-2017
 - 2.3.6 Market Analysis of Bioengineered Protein Drugs in Northwest China 2013-2017
- 2.4 Market Development Forecast of Bioengineered Protein Drugs in China 2018-2023
 - 2.4.1 Market Development Forecast of Bioengineered Protein Drugs in China 2018-2023
 - 2.4.2 Market Development Forecast of Bioengineered Protein Drugs by Regions 2018-2023

CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole China Market Status by Types

3.1.1 Consumption Volume of Bioengineered Protein Drugs in China by Types

3.1.2 Revenue of Bioengineered Protein Drugs in China by Types

3.2 China Market Status by Types in Major Countries

3.2.1 Market Status by Types in North China

3.2.2 Market Status by Types in Northeast China

3.2.3 Market Status by Types in East China

3.2.4 Market Status by Types in Central & South China

3.2.5 Market Status by Types in Southwest China

3.2.6 Market Status by Types in Northwest China

3.3 Market Forecast of Bioengineered Protein Drugs in China by Types

CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Bioengineered Protein Drugs in China by Downstream Industry

4.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in North China

4.2.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Northeast China

4.2.3 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in East China

4.2.4 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Central & South China

4.2.5 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Southwest China

4.2.6 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Northwest China

4.3 Market Forecast of Bioengineered Protein Drugs in China by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

5.1 China Economy Situation and Trend Overview

5.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BIOENGINEERED PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA

6.1 Sales Volume of Bioengineered Protein Drugs in China by Major Players

6.2 Revenue of Bioengineered Protein Drugs in China by Major Players

6.3 Basic Information of Bioengineered Protein Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Players

6.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BIOENGINEERED PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Abbott Laboratories

7.1.1 Company profile

7.1.2 Representative Bioengineered Protein Drugs Product

7.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

7.2 F. Hoffmann-La Roche Ltd

7.2.1 Company profile

7.2.2 Representative Bioengineered Protein Drugs Product

7.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd

7.3 Amgen, Inc.

7.3.1 Company profile

7.3.2 Representative Bioengineered Protein Drugs Product

7.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc.

7.4 Bayer AG

7.4.1 Company profile

7.4.2 Representative Bioengineered Protein Drugs Product

7.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG

7.5 Merck & Co., Inc.

7.5.1 Company profile

7.5.2 Representative Bioengineered Protein Drugs Product

7.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.

7.6 Dr. Reddy's Laboratories Ltd.

7.6.1 Company profile

7.6.2 Representative Bioengineered Protein Drugs Product

7.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd.

7.7 Biocon Ltd.

7.7.1 Company profile

7.7.2 Representative Bioengineered Protein Drugs Product

7.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd.

7.8 Eli Lilly and Company

7.8.1 Company profile

7.8.2 Representative Bioengineered Protein Drugs Product

7.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company

7.9 Sanofi

7.9.1 Company profile

7.9.2 Representative Bioengineered Protein Drugs Product

7.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi

7.10 GlaxoSmithKline plc

7.10.1 Company profile

7.10.2 Representative Bioengineered Protein Drugs Product

7.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc

7.11 Johnson & Johnson

7.11.1 Company profile

7.11.2 Representative Bioengineered Protein Drugs Product

7.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.12 JanssenNovartis AG

7.12.1 Company profile

7.12.2 Representative Bioengineered Protein Drugs Product

7.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG

7.13 Panacea Biotec

7.13.1 Company profile

7.13.2 Representative Bioengineered Protein Drugs Product

7.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec

7.14 ProBioGen AG

7.14.1 Company profile

7.14.2 Representative Bioengineered Protein Drugs Product

7.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

8.1 Industry Chain of Bioengineered Protein Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

9.1 Cost Structure Analysis of Bioengineered Protein Drugs

9.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs

9.3 Labor Cost Analysis of Bioengineered Protein Drugs

9.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Bioengineered Protein Drugs-China Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/B7A2AC2AC33EN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B7A2AC2AC33EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970